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1. Introduction 
Embryonic stem cells (ESC) have been reported for different mammalian species (i.e. 
hamster, rat, mink, pig, and cow), but only murine ES cells have successfully transmitted 
their cell genome through the germline. Recently, interest in stem cell technology has 
intensified with the reporting of the isolation of primate and human ES cells. 
In developing this chapter, some conventions have to be established to describe consistently 
what stem cells are, what characteristics they have, and how they are used in biomedical 
research. Also, we intend to describe and distinguish the details of foetal and adult stem 
cells. In between lie important information describing what researchers have discovered 
about stem cells  and a newly developed autologous ES cell–like stem cells, called induced 
pluripotent stem (iPS) cells. These reprogrammed stem cells (iPS) could be generated from 
any patient, thus removing both ethical and immunological issues at one time. 
A stem cell is a special kind of cell that has a unique capacity to renew itself and to give rise 
to specialized cell types. Although most cells of the body, such as heart or skin cells, are 
committed to conduct a specific function, a stem cell is uncommitted and remains 
uncommitted, until it receives a signal to develop into a specialized cell. Their proliferative 
capacity combined with the ability to become specialized makes stem cells unique. 
Stem cells can originate from embryonic, foetal, or adult tissue and are broadly categorized 
accordingly.  
Embryonic Stem Cells (ESCs) are commonly derived from the inner cell mass (ICM) of a 
blastocyst, an early (4–5 days) stage of the embryo. Embryonic germ cells (EGCs) are 
isolated from the gonadal ridge of a 5–10 week foetus.  
Adult stem cells differ from ESCs and EGCs in that they are found in tissues after birth, and 
to date, have been found to differentiate into a narrower range of cell types, primarily those 
phenotypes found in the originating tissue. An adult stem cell is thought to be an 
undifferentiated cell, found among differentiated cells in a tissue or organ that can renew 
itself and can differentiate to yield some or all of the major specialized cell types of the tissue 
or organ. The primary roles of adult stem cells in a living organism are to maintain and 
repair the tissue in which they are found, because they are able to self-renew and yield 
differentiated cell types.  
They are thought to reside in a specific area of each tissue (called a "stem cell niche"). Stem 
cells may remain quiescent (non-dividing) for long periods of time until they are activated 
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by a normal need for more cells to maintain tissues, or by disease or tissue injury. Typically, 
there is a very small number of stem cells in each tissue, and once removed from the body, 
their capacity to divide is limited, making generation of large quantities of stem cells 
difficult. Today, donated organs and tissues are often used to replace those that are diseased 
or destroyed. Unfortunately, the number of people needing a transplant far exceeds the 
number of organs available for transplantation. Adult stem cells, such as blood-forming 
stem cells in bone marrow (called hematopoietic stem cells, or HSCs), are currently the only 
type of stem cell commonly used to treat human diseases.  
Scientists in many laboratories are trying to find better ways to manipulate them to generate 
specific cell types so they can be used to treat injury or disease. Pluripotent stem cells offer 
the possibility of a renewable source of replacement cells and tissues to treat a myriad of 
diseases, conditions, and disabilities including Parkinson's disease, Amyotrophic Lateral 
Sclerosis, spinal cord injury, burns, heart disease, diabetes, and arthritis. This pluripotency 
represents both advantages and disadvantages in cell-based therapies. In fact for culture in 
vitro, their ability to generate the large number of cells often required for therapies, as well 
as their potential to yield whichever phenotype may be of interest, is considered beneficial. 
For implantation in vivo, however, the concern arises that these same attributes will either 
allow ESCs to proliferate limitlessly and form teratomas or differentiate uncontrollably into 
undesirable cell phenotypes.  
Several are the applications of ESCs in human medicine: tissue repair, gene therapy, drug 
discovery and toxicological testing.   
Stem cells are promising tools for studying the mechanisms of development and 
regeneration and for use in cell therapy of various disorders as cardiovascular disease and 
myocardial infarction (MI), brain and spinal cord injury, stroke, diabetes and cartilage. 
Although hESC are thought to offer potential cures and therapies for many devastating 
diseases, research using them is still in its early stages. 
In late January 2009, the California-based company Geron received FDA clearance to begin 
the first human clinical trial of cells derived from human embryonic stem cells. 
But some scientific hurdles to hESCs application have to be deeply considered: 
• the rejection of transplanted tissues (originating from donor embryos);  
• the risk of teratoma formation due to any residual rogue undifferentiated pluripotent 
hESCs in the hESC-derived tissue (after the differentiation process);  
• the inadequate number of cells available for treatment (for obtaining a large numbers of 
cells, large-scale cell production strategies are needed utilizing bioreactors and 
perfusing systems); 
• the safety measures to be taken when a whole cell is administered because a variety of 
impurities may be administered with it (cells cells must be generated under cGMP 
current good tissue culture practice conditions using xenofree protocols to prevent the 
risk of transmission of adventitious agents and rogue undifferentiated hESCs that may 
induce teratomas); 
• the best route and the frequency of administration (direct cell injections into the 
malfunctioned organ would be preferred to peripheral or portal vein administration to 
prevent the cells homing in unwanted sites, thus inducing cancers).  
For the above reasons a long-term in vivo functional outcome after hESC-derived tissue 
transplantation also needs to be properly worked out. 
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2. Origin and classification of stem cells 
Human stem cells can be classified into many types based on their source of origin. More 
recently, they have been classified based on the presence or absence of a battery of CD and 
embryonic stem cell (ESC) markers.  
The male and female gonads contain stem cells referred to as spermatogonia and oogonia, 
respectively. Through their self-renewal and subsequent meiosis they are responsible in 
producing the cells of the germ line and eventually spermatozoa and oocytes. These two 
haploid gametes eventually fertilize to establish diploidy and produce the zygote. The 
zygote remains at the top of the hierarchical stem cell tree, being the most primitive cell, and 
the germ cells therefore possess the unique feature of developmental totipotency 
(Yoshimizu T et al. 1999; Pesce et al 1998). The zygote undergoes cleavage in the human 
through a period of 5–6 days, producing two to four blastomeres on day 2, eight  on day 3, 
fusing or completely fused blastomeres (compacting or compacted stage) on day 4, and 
blastocyst stages on days 5 and 6 (Bongso et al 2005; Fong et al 2004). Each of the 
blastomeres is considered totipotent because it has the potential to produce a complete 
organism, as demonstrated when blastomeres are placed into the uterus of rabbits or mice. 
The first stem cell to be produced in the mammal is in the inner cell mass (ICM) of the 5-
day-old blastocyst. These cells self-renew and eventually produce two cell layers: the 
hypoblast and epiblast. The hypoblast generates the yolk sac, which degenerates in the 
human, and the epiblast produces the three primordial germ layers (ectoderm, mesoderm, 
and endoderm). These germ layers produce all the various tissues of the organism. For this 
reason hESCs are considered pluripotent and not totipotent because they cannot produce 
complete human beings but have the potential to produce all the 210 tissues of the  
human body.  
During embryogenesis and fetal growth such embryonic stem cells that have not 
participated in organogenesis remain as adult stem cells in organs during adulthood. It can 
thus be hypothesized that the function of adult stem cells residing in specific organs is to be 
dedifferentiated and be recruited for repair of injury incurred by the specific organ. 
Unfortunately, such adult stem cells in the organs are few in number. 
It has been shown that fetal and adult stem cells, referred to as somatic stem cells or non-
embryonic stem cells, are able to self-renew during the lifetime of the organism and to 
generate differentiated daughter cells. Moreover they could cross boundaries by trans-
differentiating into other tissue types and are thus referred to as multipotent [Solter et al., 2006,  
Bjornson CR, et al 1999; Jackson KA, et al 1999;Clarke DL et al 2000 ; Krause DS et al 2001].  
Adult tissues, even in the absence of injury, continuously produce new cells to replace those 
that have worn out. For this reason, adult stem cells can be found in a metabolically 
quiescent state in most specialized tissues of the body, including brain, bone marrow, liver, 
skin, and the gastrointestinal tract. Therefore, multipotency is restricted to those 
mesenchymal stem cell types that can differentiate into a small variety of tissues. 
Those stem cells that are unable to trans-differentiate but differentiate into one specific 
lineage are referred to as unipotent. An example of such unipotency is the differentiation of 
bone marrow hematopoietic stem cells to blood. Thus as embryogenesis shifts to 
organogenesis, infancy, and then adulthood, stem cell plasticity shifts from pluripotency to 
multipotency.  
Recently there has been tremendous interest in the derivation from embryonic, fetal and 
adult tissues and, more recently, also from extra-embryonic adnexa such as umbilical cord, 
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placenta, fetal membranes and amniotic fluid.[ Zhao et al 2006; McGuckin CP et al. 2005 ; 
Fong CY ,et al. 2007] . These tissues  possess both CD and some ESC markers, and thanks to 
their “intermediate” properties, are considered useful for transplantation therapy [Fong et al 
2007] . The umbilical cord, for example, has three types of stem cells localised  in cord blood, 
in the Wharton’s jelly, and in the perivascular matrix around the umbilical blood vessels 
within the cord itself [Sarugaser et al. 2005] . 
3. Stem cells characteristics 
The term “stem cell” originated from botanical monographs where the word “stem” was 
used for cells  localised in the apical meristem, and responsible for the continued growth of 
plants [Kaufman et al 2002]. In mammals, given the vast variety of stem cells isolated from 
pre-implantation embryos, fetus, amniotic liquid, umbilical cord, and adult organs, it 
becomes necessary to provide a more general definition for the term “stem cell” and a more 
specific definition based on the type of stem cell. 
In general, stem cells differ from other kinds of cells in the body, and have dual ability to 
proliferate indefinitely (i.e. self renewal) and to differentiate into one or more types of 
specialized cells (i.e. potency) [Mimeault and Batra 2006]. 
Stem cells are capable of dividing and renewing themselves for long periods. Unlike muscle, blood, 
or nerve cells—which do not normally replicate themselves—stem cells may replicate many 
times, or proliferate. A starting population of stem cells that proliferates for many months in 
the laboratory can yield millions of cells. If the resulting cells continue to be unspecialized, 
like the parent stem cells, the cells are said to be capable of long-term self-renewal. 
Stem cells are unspecialized. One of the fundamental properties of a stem cell is that it does not 
have any tissue-specific structures that allow it to perform specialized functions.  However, 
unspecialized stem cells can give rise to specialized cells, including heart, muscle, blood  or 
nerve cells. 
Stem cells can give rise to specialized cells. When unspecialized stem cells give rise to 
specialized cells, the process is called differentiation. While differentiating, the cell usually 
goes through several stages, becoming more specialized at each step. Scientists are just 
beginning to understand the signals inside and outside cells that trigger each step of the 
differentiation process. The internal signals are controlled by cell's genes carrying coded 
instructions for all cellular structures and functions. The external signals for cell 
differentiation include chemicals secreted by other cells, physical contact with neighboring 
cells, and certain molecules within the microenvironment. The interaction of signals during 
differentiation causes the cell's DNA to acquire epigenetic marks that restrict DNA 
expression in the cell and can be passed on through cell division. 
The degree of differentiation of stem cells to various other tissue types varies with the 
different types of stem cells, and this phenomenon is referred to as plasticity. 
The plasticity of stem cells and differentiated cells in the postnatal organism poses 
important questions concerning the role of environmental cues. What mechanisms allow a 
stem cell to escape developmental pressures and maintain its “stemness”? What macro- or 
micro-environmental cues maintain a cell in its differentiated state? Other important 
questions to solve are related to the developmental origin of postnatal stem cells, to their 
possible relationships, as well as the role of symmetrical and asymmetrical cell divisions 
that maintain stem cell compartments but allow for differentiation in the same time [Booth, 
and Potten 2000; Morris, R. 2000] 
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4. Embryonic stem cell: hESCs and mESCs 
Embryonic stem (ES) cells were first isolated in the 1980s by several independent groups 
[Cole et al., 1965, 1966; Evans and Kaufman, 1981; Martin, 1981; Bongso et al., 1994; 
Thomson et al., 1995, 1998; Axelrod,1984; Wobus, et al.1984; . Doetschman et al. 1985]. These 
investigators recognized the pluripotential nature of ES cells to differentiate into cell types 
of all three primary germ lineages. Gossler et al. described the ability and advantages of 
using ES cells to produce transgenic animals [Gossler et al 1986]. Thomas and Capecchi 
reported the ability to alter the genome of the ES cells by homologous recombination 
(Thomas et al 1987). Smithies and colleagues later demonstrated that ES cells, modified by 
gene targeting when reintroduced into blastocysts, could transmit the genetic modifications 
through the germline [Koller at al 1989]. Today, genetic modification of the murine genome 
by ES cell technology is a seminal approach to understanding the function of mammalian 
genes in vivo. Successively, interest in stem cell technology has intensified with the reporting 
of the isolation of primate and human ES cells [Thomson et al., 1995, 1998; Shamblott et al 
1998; Reubinoff et al. 2000]. 
Embryonic Stem Cells (ESCs) continue to grow indefinitely in an undifferentiated diploid 
state, when maintained in optimal conditions. ES cells are sensitive to pH changes, 
overcrowding, oxygen and temperature changes, making it imperative to care for these cells 
daily. ES cells that are not cared for properly will spontaneously differentiate, even in the 
presence of feeder layers and leukemia inhibitory factor (LIF). 
Embryonic stem cells have the advantages of possessing pluripotent markers, producing 
increased levels of telomerase, and being coaxed into a whole battery of tissue types. On the 
other side they have the disadvantages of potential teratoma production, their derived 
tissues have to be customized to patients to prevent immunorejection, and their numbers 
have to be scaled up in vitro for clinical application.  
Since the first report of ESC derivation in mice was published in 1981, [Evans and Kaufman 
1981] various findings have emerged to explain the basic properties of ESCs. Recent 
advances in our understanding of ESC biology have included the identification of several 
master regulators of ESC pluripotency and differentiation. However, intensive study of ESC 
growth conditions has yet to produce a complete picture of the unique transcriptional and 
epigenetic state that is responsible for pluripotency and self-renewal in ESCs. 
In summary, genuine hESC have the following characteristics: (1) self-renewal in an 
undifferentiated state for very long periods of time with continued release of large amounts of 
telomerase, (2) maintenance of “stemness” or pluripotent markers, (3) formation  of teratoma 
containing tissues from all three primordial germ layers when inoculated in SCID mice, (4) 
maintenance of a normal stable karyotype, (5) clonality, (6) stem cells marker  expression (e.g., 
NANOG), and (7) ability to produce chimeras when injected into blastocysts in the mouse 
model.  
hESCs have many applications in human medicine. First of all the production of hESC-
derived tissues in regenerative therapy.  
5. Using pluripotent stem cells in clinic issues 
A number of scientific and medical issues need to be addressed before stem cells can be 
considered safe for clinical applications. The first difficulty is the tumorigenic potential of 
pluripotent cells (hESCs and iPSCs). Because pluripotency is evidenced by the ability to 
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form teratomas when transplanted in immunodeficient mice, the concern exists that these 
cells could form malignant tumors in the host. One strategy for dealing with this problem is 
to select pure populations of more committed cells for transfer. Therefore it is important 
demonstrating the genetic and epigenetic stability before these cells are used clinically. In 
fact is imperative that controlled, standardized practices and procedures be followed to 
maintain the integrity, uniformity, and reliability of the human stem cell preparations. 
Because in many studies stem cells are both maintained and expanded in vitro before 
transplantation, culture conditions compatible with human administration must be used. 
Feeder cells and sera of animal origin have to be avoided to reduce the potential risk of 
contamination by xenogeneic protein and pathogens. Also karyotypic abnormalities, might 
be at least partially dependent on culture techniques [Mitalipova et al. 2005]. Accordingly  
hESCs must be produced under current Good Manufacturing Practices (cGMP) quality. That 
is defined by both the European Medicines Agency and the Food and Drug Administration, 
as a requirement for clinical-grade cells, offering optimal defined quality and safety in cell 
transplantation. In Europe, the requirement for cell therapy products is outlined in several 
directives and guidelines that are pertinent as regards hESCs (Directive 2004/23/EC, 
Commission Directives 2006/17/EC and 2006/86/EC). 
Finally, transplantation of hESCs into patients is also limited by potential HLA 
incompatibility. Consequently, life-long immunosuppressive therapy, which can lead to 
infections and organ-based toxic side effects, such as nephropathy, might be required to 
prevent graft rejection.  
In this regard induced Pluripotent Stem Cells  (iPSCs) hold great promise because they are 
histocompatible with the patient from which they are derived and their use avoids one of 
the major ethical concerns associated with hESCs.  
6. ESCs cell therapy in vivo and in vitro 
The NIH funded its first basic research study on hESCs in 2002. Since that time, 
biotechnology companies have built upon those basic foundations to begin developing stem 
cell-based human therapies. 
Cell therapy, including the disciplines of regenerative medicine, tissue-, and bio-
engineering, is dependent on cell and tissue culture methodologies to generate and expand 
specific cells in order to replace important differentiated functions lost or altered in various 
disease states (i.e. no insulin production in diabetes). Central to the successful development 
of cell based therapies is the question of cell sourcing. Thus, advances in stem cell research 
have a vital impact on this problem.  
The use of human ESCs as resource for cell therapeutic approaches is currently performed 
for several diseases. Among these we are going to describe myocardium diseases and lung 
disease. 
The Landmark’s study is the first to document the potential clinical utility of regenerating 
damaged heart muscle by injecting hESC–derived cardiomyocytes directly into the site of 
the infarct [Laflamme MA et al., 2007]. Researchers have demonstrated the proof-of-concept 
of this approach in mice. Mouse embryonic stem cells have been used to derive mouse 
cardiomyocytes. When injected into the hearts of recipient adult mice, the cardiomyocytes 
repopulated the heart tissue and stably integrated into the muscle tissue of the adult mouse 
heart. After that, they have derived human cardiomyocytes from hESCs (GRNCM1) using a 
process that can be scaled for clinical production. GRNCM1 cells shown normal contractile 
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function and responded appropriately to cardiac drugs. These cells have been transplanted 
into animal models of myocardial infarction in which the cells engraft and improve the left 
ventricular function compared to those animals receiving no cells. The ability of hES cell–
derived cardiomyocytes to partially regenerate myocardial infarcts and attenuate heart 
failure encouraged their study under conditions that closely match human disease. 
In 2007 another study showed that intramyocardial injection of hESC-CMs performed few 
days after infarction in immunodeficient rodents seemed to enhance left ventricular ejection 
fraction (LVEF) compared to a control group [van Laake LW et al 2007]. 
Unfortunately, this enhancement was not sustained after 12 weeks of follow-up. Another 
study suggested that a coinfusion of hESC-CMs and MSCs in mice was of benefit because a 
‘‘synergistic trophic effect that enhanced repair of injured host tissue’’ was brought about. 
Importantly, no teratoma was found in animals receiving hESC-CMs [van Laake LW et al 
2007 ; Puymirat et al 2009]. 
Respiratory diseases are a major cause of mortality and morbidity worldwide. Current 
treatments offer no prospect of cure or disease reversal. Transplantation of pulmonary 
progenitor cells derived from human embryonic stem cells (hESCs) may provide a novel 
approach to regenerate endogenous lung cells destroyed by injury and disease. In a study 
researcher examine the therapeutic potential of alveolar type II epithelial cells derived from 
hESCs (ATIICs) in a nude mouse model of acute lung injury (Spitalieri P. et al. submitted).  
The capacity of hES to differentiate in vitro into ATIICs was demonstrated together with the 
ability of the above committed cells to repair in vivo lung damage in a pulmonary fibrosis 
disease models, obtained by Silica inhalation in mice. After injection of committed cells into 
damaged mice, a significant recovery of inflammation process and fibrotic damage, was 
obtained and demonstrated by the restoration of lung functionality (measurement of blood 
oxygen saturation levels). 
Up to date in human only one trial based on hESCs has been initiated. During July 2010, the 
FDA notified the biotechnology company Geron that they could begin enrolling patients in 
the first clinical trial of a hESC-derived therapy. The phase I of this multi-center trial is 
designed to establish the safety of using hESCs to achieve restoration of spinal cord 
function. To do this, they have derived oligodendrocyte progenitor cells (GRNOPC1) from 
hESCs. GRNOPC1 is a population of living cells containing precursors to oligodendrocytes, 
otherwise known as oligodendrocyte progenitor cells (OPC). Oligodendrocytes are naturally 
occurring cells in the nervous system that have several functions, they produce myelin 
(insulating layers of cell membrane) that wraps around the axons of neurons to enable them 
to conduct electrical impulses. 
In collaboration with researchers at the University of California, Geron have shown in 
animal models that GRNOPC1 can improve functional locomotor behaviour after cell 
implantation in the damaged site, seven days after injury. Histological analysis also 
provided evidence for the engraftment and function of these cells [Keirstead HS et al 2005].  
In additional studies, GRNOPC1, when injected into the injury site of spinal cord, migrated 
throughout the lesion site matured into functional oligodendrocytes that remyenilated 
axons and produced neurotrophic factors [Zhang YW et al. 2006], resulting in improved 
locomotion of the treated animals. These above observations served as the rationale for the 
use of GRNOPC1 in treating spinal cord injuries in humans. 
The clinical hold was placed following results from a single preclinical animal study in 
which Geron observed a higher frequency of small cysts within the injury site in the spinal 
cord of animals injected with GRNOPC1, respect to previous studies. In response to those 
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results, Geron developed new markers and assays, completed an additional confirmatory 
preclinical animal study to test the new markers and assays, and subsequently submitted a 
request to the FDA for the clinical hold to be lifted. 
Another biotech company, ACT, has recently filed the paperwork with FDA to request 
permission to begin another hESC-derived stem cell safety test.  The trial regard the 
treatment of patients with an eye disease called Stargardt’s Macular Dystrophy (SMD), 
using hES-derived retinal cells. 
7. Adult stem cell 
For many years, researchers have been seeking to understand the body's ability to repair 
and replace the cells and tissues of some organs. Scientists have now focused their attention 
on adult stem cells. It has long been known that stem cells are capable of renewing 
themselves and that they can generate multiple cell types. Today, there is new evidence that 
stem cells are present in far more tissues and organs than once thought and are capable of 
developing into more kinds of cells than previously imagined. Efforts are now underway to 
harness stem cells and to take advantage of this capability, with the goal of devising new 
and more effective treatments. What lies ahead for the use of adult stem cells is unknown, 
but it is certain that there are many research questions to be answered and that these 
answers hold great promise for the future. 
Adult stem cells share at least two characteristics. First, they can make identical copies of 
themselves for long periods of time; this ability to proliferate is referred to as long-term self-
renewal. Second, they can give rise to mature cell types that have characteristic 
morphologies and specialized functions.  
Typically, stem cells generate an intermediate cell type or types before they achieve their 
fully differentiated state. The intermediate cell is called a precursor or progenitor cell. 
Progenitor or precursor cells in fetal or adult tissues are partly differentiated cells that 
divide and give rise to differentiated cells. Such cells are usually regarded as "committed" to 
differentiate along a particular cellular development pathway, although this characteristic 
may not be as definitive as once thought [Marcus A. et al. 2008]. 
Unlike embryonic stem cells, which are defined by their origin, adult stem cells share no 
such definitive means of characterization. In fact, no one knows the origin of adult stem cells 
in any mature tissue. Some have proposed that stem cells are somehow set aside during fetal 
development and restrained from differentiating. The list of adult tissues reported to 
contain stem cells is growing and includes bone marrow, peripheral blood, brain, spinal 
cord, dental pulp, blood vessels, skeletal muscle, epithelia of the skin and digestive system, 
cornea, retina, liver, and pancreas. 
In the next part of the chapter we will refer only to fetal and adult stem cells. 
8. Fetal Stem Cells 
In recent years, foetal stem cells (FSCs) and stem cells isolated from cord blood or 
extraembryonic tissues have emerged as a potential ‘half way house’ between ES cells and 
adult stem cells. FSCs can be found in foetal tissues such as chorionic villus sampling (CVS) 
blood, liver, bone marrow, pancreas, spleen and kidney. They are also found in cord blood 
and extraembryonic tissues such as amniotic fluid, placenta and amnion [Marcus A et al 
2008]. Their primitive properties, expansion potential and lack of tumorigenicity make them 
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an attractive option for regenerative medicine in cell therapy and tissue engineering 
settings. While extraembryonic tissues could be used with few ethical reservations, the 
isolation of FSCs from abortuses is subject to significant public unease. We review here the 
characteristics of stem cells from foetal, cord blood and extra embryonic tissues, their 
application in cell therapy and their potential for reprogramming towards pluripotency. 
Fetal stem cells are advantageous for research for some relevant reasons.  
First, they could be obtained from minimally invasive techniques during the gestation, for 
prenatal diagnosis. A number of studies followed, reporting that preparations of amniotic 
epithelial cells (AECs), amniotic mesenchymal cells (AMCs), and cells collected from 
amniotic fluid (AFCs), seem to contain cells with certain stem cell properties. These cells 
possess a high proliferation potential, express markers (such as OCT4) specific to 
pluripotent stem cells, and display the potential to differentiate in vitro into cells of all three 
germ layers [Alviano F. et al. 2007;De Coppi P. et al. 2007; Ilancheran S., et al 2007 Kim, J. et 
al 2007; Miki, T et al 2005;Tamagawa T. et al 2007; Zheng Y.B et al. 2008 ]. 
Second, fetal stem cells have a higher potential for expansion than cells taken from adults. 
Mesenchymal cells from umbilical cord blood can be induced to form a variety of tissues 
when cultured in vitro, including bone, cartilage, myocardial muscle, and neural tissue 
[Bieback et al 2004]. Third, the ability to isolate pluripotent autogenic progenitor cells during 
gestation may be advantageous for the timely treatment of congenital malformations or 
genetic diseases in newborns (in utero therapy). Fourth, their use is devoid of the ethical 
issues associated with embryonic stem cells [Weiss, M.L., and Troyer, D.L.2006]. Recently, a 
new source of human amniotic fluid stem cells (hAFSC) has been isolated [De Coppi et al 
2007]. These cells represent 1% of the population of cells obtained from amniocentesis and 
are characterized by the expression of the receptor for stem cell factor c-Kit (CD117). hAFSC 
are multipotent, showing the ability to differentiate into lineages belonging to all three germ 
layers, and can be propagated easily in vitro without the need of a feeder layer. hAFSC 
express the markers OCT4 and SSEA-4, both of which are typical of the undifferentiated 
state of embryonic stem cells (ESC). However, hAFSC do not express some of the other 
typical markers of ESC, such as SSEA-3, and instead express mesenchymal and neuronal 
stem cell markers (CD29, CD44, CD73, CD90, and CD105) that are normally not expressed in 
ESC. Therefore, hAFSC can be considered as an intermediate type of stem or progenitor cell 
between ESC and adult stem cells resident in differentiated organs. 
Although AFS cells have been recently discovered and many questions concerning their 
potential are still open, they appear to harbour specific advantages in comparison to other 
stem cell populations: (1) they can be easily harvested through amniocentesis, which is a safe 
procedure routinely performed for the antenatal diagnosis of genetic diseases [Caughey AB et 
al 2006]; (2) they do not form tumours after implantation in vivo [De Coppi et al 2007]; (3) 
obtaining them during pregnancy is harmful neither to the mother nor to the foetus [Caughey 
AB, et al 2006;Eddleman KA,et al., 2006; Cananzi M, et al 2009]. Moreover, recent papers have 
demonstrated that, when injected in models of organ damage and development, AFS cells are 
able to: integrate into the developing kidney and express early markers of renal differentiation 
[Perin L et al 2007]; repopulate the bone marrow of immunocompromised mice after primary 
and secondary transplantation [Ditadi A et al. 2009], and engraft into the lung, differentiating 
into pulmonary lineages [Carraro G et al 2008] respectively. 
A recent study reported for the first time a detailed characterization of the differentiation 
capability of fetal cells obtained from chorionic villus sampling (CVS) [Spitalieri P et al 
2009]. CVSs can be routinely obtained during early pregnancy for prenatal diagnosis 
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purposes, can be easily cultured in vitro and modified by gene targeting protocols for cell 
therapy applications [D’Alton, M.E. 1994.; d’Ercole, C.,et al. 2003;Sangiuolo, F.et al 2005]. 
The study investigated whether cells with phenotypic and functional characteristics of stem 
cells are present within human CVSs harvested from the 9th to 12th week of gestation 
during routine chorionic villus sampling. Results indicate that human CV cytotrophoblasts 
contains a cell population expressing typical markers, able to differentiate in vitro into 
derivatives of all three germ layers and also able to populate depleted hematopoietic tissues.  
Moreover these cells, after injection into mouse blastocysts were incorporated into the inner 
cell mass and could be traced into several tissues of the adult chimeric mice. Finally no 
teratoma formation was reported after cell injection into SCID mice, demonstrating their 
usefulness in cell and gene therapy approach. 
9. Adult Stem Cells: Hematopoietic Stem Cells (HSCs) and Mesenchymal 
Stem Cell (MSCs) 
Specialized connective tissues consist of blood, adipose tissue, cartilage, and bone. It has 
been generally believed that all cellular elements of connective tissue, including fibroblasts, 
adipocytes, chondrocytes, and bone cells, are generated solely by mesenchymal stem cells 
(MSCs) [Ashton BA, et al 1980; Prockop DJ.et al 1997; Pittenger MF, et al 999; Bianco P, et al 
2008; Studeny M, et al 2002; Verfaillie CM, et al 2003; Gregory CA, et al 2005], while blood 
cells are produced by hematopoietic stem cells (HSCs).  
Bone marrow (BM) is a complex tissue containing hematopoietic progenitor cells and a 
connective-tissue network of stromal cells.  
The continued production of these cells depends directly on the presence of Hematopoietic 
Stem Cells (HSCs), the ultimate, and only, source of all these cells. 
The term mesenchymal stem cells was coined by Caplan [Caplan AI.et al 1991] in 1991 to 
describe a population of cells present within the adult bone marrow that can be stimulated 
to differentiate into bone and cartilage, tendon, muscle, fat [Alhadlaq A., and Mao JJ. 2003; 
Alhadlaq A., et al 2004; Pittenger MF,et al 1999;], and marrow stromal connective tissue 
which supports hematopoietic cell differentiation [Dexter TM et al.1976;Friedrich C. et al. 
1996].  In addition, controversial data suggest that MSCs may give rise to sarcomeric muscle 
(skeletal and cardiac) [Wakitani S, et al. 1995; Makino S, et al 1999; Planat-Bénard V, 2004;], 
endothelial cells [Oswald J,et al 2004] and even cells of non-mesodermal origin, such as 
hepatocytes [Chagraoui J, et al 2003], neural cells [Woodbury D, et al., 2000] and epithelial 
cells [Spees JL,  et al. 2003; Ma Y, et al 2006] MSCs represent a very small fraction, 0.001–
0.01% of the total population of nucleated cells in marrow [Pittenger MF et al.,  1999].  
Although Bone Marrow (BM) has been represented as the main available source of MSCs 
[Pittenger MF et al 1999 ; Haynesworth SE et al.  1992], the use of bone marrow-derived cells 
is not always acceptable because of potential viral exposure and a significant decrease in the 
cell number along with age. In addition, it requires a painful invasive procedure to obtain a 
BM sample. Therefore, the identification of alternative sources of MSCs may provide 
significant clinical benefits with respect to ease of accessibility and reduced morbidity. 
The umbilical cord blood (UCB) has been used as an alternative source since 1988 
[Gluckman E et al 1989].  The blood remaining in the umbilical vein following birth contains 
a rich source of hematopoietic stem and progenitor cells (HSCs/HPCs), and has been used 
successfully as an alternative allogeneic donor source to treat a variety of pediatric genetic, 
hematologic, immunologic, and oncologic disorders [Broxmeyer HE, et al1989; Gluckman E, 
et al 1997; Han IS, 2003; Kim SK, et al 2002]. 
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9.1 MSCs and HSCs: Cell and gene therapy 
Stem cell therapies utilizing adult mesenchymal stem cells (MSCs) are the focus of a 
multitude of clinical studies currently underway. Because large numbers of MSCs can be 
generated in culture, MSCs were thought to be useful for ‘‘tissue-engineering’’ purposes 
[Caplan AI, et al 2001], as exemplified by a number of clinical trials [Dazzi F, et al 2007; 
Prockop DJ, et al  2007]. 
MSCs are multipotent cells with the capacity to differentiate to produce multiple types of 
connective tissue and down-regulate an inflammatory response. MSC are being explored to 
regenerate damaged tissue and treat inflammation, resulting from cardiovascular disease 
and myocardial infarction (MI), brain and spinal cord injury, stroke, diabetes, cartilage and 
bone injury, Crohn’s disease and graft versus host disease (GvHD) [Phinney DG et al. 2007]. 
Few years after multipotent MSCs were identified (1980), human trials were commenced to 
evaluate safety and efficacy of MSC therapy.  
MSC transplantation is considered safe and has been widely tested in clinical trials of 
cardiovascular [Ripa RS et al 2005; Chen SL et al. 2004], neurological [Lee PH et al 2008; 
Bang OY et al 2005], and immunological disease [Lazarus et al 2005; Ringden O et al 2006] 
with encouraging results. 
Widely described above, MSCs are an excellent candidate for cell therapy  because (a) 
human MSCs are easily accessible; (b) the isolation of MSCs is straightforward and this stem 
cells can expand to clinical scales in a relatively short period of time [Colter DC  et al 2000; 
Sekiya I et al 2002]; (c) MSCs can be bio-preserved with minimal loss of potency [Lee MW et 
al 2005; Ripa RS et al 2005]; and (d) human trials using MSCs thus far have shown no 
adverse reactions to allogeneic versus autologous MSC transplants. 
More recently, a new study shows that umbilical cord mesenchymal stem cell transplant 
(UC-MSCt) may improve symptoms and biochemical values in patients with severe 
refractory systemic lupus erythematosus (SLE) [Sun L et al 2010]. Authors reported a clinical 
trials on 16 patients with severe SLE that did not respond to standard treatments [Sun L et al 
2010]. After receiving umbilical mesenchymal stem cell transplants, 10 of them completed at 
least 6 months of follow- up. There was no treatment-related mortality or other adverse 
events. All patients achieved at least 3 months of clinical and serologic improvement, and 
for two of them this was achieved without any immunosuppressive drugs. For the first time 
allogenic UC-MSC transplanatation was shown to be safe and effective, at least short term, 
in treating patients with severe SLE. 
HSCs were successfully employed in gene therapy protocols. An ADA-SCID (Adenosine 
Deaminase Severe Combined Immunodeficiency) clinical trial was performed on 10 affected 
childrens [Aiuti A et al 2009]. ADA-SCID is one of the most promising conditions for 
treatment with combine gene therapy and cell therapy and has been the source of early 
successes in the field. Autologous CD34+ bone marrow cells transduced with a retroviral 
vector containing the ADA gene were infused into 10 children with SCID due to ADA 
deficiency who lacked an HLA-identical sibling donor, after non-myeloablative 
conditioning with busulfan.  
In vivo  trials have  showed a relevant restored immunity in patients treated by a combination 
of cell and gene therapy protocol, confirmed in the long-term outcome. After about 10 years, 
all patients are alive after a median follow-up of 4.0 years and transduced hematopoietic stem 
cells have stably engrafted and differentiated into myeloid cells containing ADA and 
lymphoid cells. Eight patients do not require enzyme-replacement therapy because their blood 
cells continue to express ADA. Nine patients had immune reconstitution with increases in T-
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cell counts and normalization of T-cell function. In five patients in whom intravenous immune 
globulin replacement was discontinued, antigen-specific antibody responses were elicited after 
exposure to vaccines or viral antigens. Effective protection against infections and improvement 
in physical development made a normal lifestyle possible. Serious adverse events were 
reported including prolonged neutropenia (in two patients), hypertension (in one), central-
venous-catheter-related infections (in two), Epstein-Barr virus reactivation (in one), and 
autoimmune hepatitis (in one). 
Another clinical trial was reported reviewing long-term outcome nine patients with X-
linked severe combined immunodeficiency (SCID-X1), which is characterized by the absence 
of the cytokine receptor common gamma chain. These patients, who lacked an HLA-
identical donor, underwent ex vivo retrovirus-mediated transfer of gamma chain to 
autologous CD34+ bone marrow cells between 1999 and 2002. The immune function on 
long-term follow-up was also assessed [Salima Hacein-Bey-Abina et al 2010]. 
Gene therapy was initially successful at correcting immune dysfunction in eight of the nine 
patients. Transduced T cells were detected for up to 10.7 years after gene therapy but 
however, acute leukemia developed in four patients, and one died. Seven patients had 
sustained immune reconstitution and three patients required immunoglobulin-replacement 
therapy. Sustained thymopoiesis was established by the persistent presence of naive T cells 
and the correction of the immunodeficiency improved the patients' health. 
So, after nearly 10 years of follow-up, gene therapy was shown to have corrected the 
immunodeficiency associated with SCID-X1.  
Another recent study was published reporting the successful application of a gene therapy 
protocol by using lentiviral β-globin gene transfer in an adult patient with severe β(E)/β(0)-
thalassaemia dependent on monthly transfusions since early childhood. About 33 months after 
the treatment, the patient has become transfusion independent for the past 21th months. 
These results are not only important due to the tremendous medical need that exists for 
thalassemia patients around the world, but also represents a significant step forward for the 
field of autologous stem cell therapy as an emerging therapeutic modality [Cavazzana-
Calvo et al., 2010]. 
Today, gene therapy may be an option for patients who do not have an HLA-identical donor 
for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable 
even if this treatments are associated associated with a risk of acute leukemia.  
10. Induced Pluripotent Stem cells (iPS) 
In 2006 researchers at Kyoto University identified conditions that would allow specialized 
adult murine cells, specifically fibroblasts, to be genetically “reprogrammed” to assume a 
stem cell-like state, by retrovirally transducting four important stem cell factors (OCT4, 
SOX2, KLF4 and c-MYC) into them.[Takahashi K et al 2006]. These cells, called “iPSCs” for 
induced pluripotent stem cells, were in this way genetically reprogrammed by being forced 
to express genes which themselves regulate the function of other genes important for early 
steps in embryonic development. These factors were involved in the maintenance of 
pluripotency, which is the capability to generate all other cell types of the body.  
Mouse iPSCs demonstrated important characteristics of pluripotent stem cells: they express 
stem cell markers, form tumors containing cells from all three germ layers, and are also able 
to contribute to many different tissues, when injected into mouse embryos at a very early 
stage during development. After one year the same author, using similar experimental 
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design and the same four genetic factors, reprogrammed also adult human dermal 
fibroblasts to iPSCs [Takahashi K et al 2007]. Human iPSCs were similar to embryonic stem 
cells (ESCs) in numerous ways: morphology, proliferative capacity, expression of cell 
surface antigens, and gene expression. They could also differentiate into cell types from the 
three embryonic germ layers both in vitro and in teratoma assays. At the same time 
Thomson and coworkers published a separate manuscript that detailed the creation of 
human iPSCs through somatic cell reprogramming using four genetic factors, two of which 
were in common with those reported above[Yu J et al 2007]. These cells met all  defining 
criteria for ES cells, with the exception that they were not derived from embryos.  
Despite these common features, it is not known if iPSCs and ESCs differ in clinically 
significant ways.  
First of all, it has to be considered that direct reprogramming was originally achieved by 
retroviral transduction of transcription factors. Retroviruses are highly efficient gene-
transfer vehicles because they provide prolonged expression of the transgene after genomic 
integration and have low immunogenicity. Successively lentiviral vectors was successfully 
employed to generate hiPSCs from various cell types, including skin fibroblasts, 
keratinocytes [Maherali N et al 2008], and adipose stem cells [Wu X et al 2003]. Lentiviruses 
are a subclass of retroviruses capable of transducing a wide range of both dividing and non-
dividing cells [Sun N et al 2009]. 
While for retroviruses, silencing in pluripotent cells is almost complete and provides a way 
to identify fully reprogrammed clones [Hotta A et al 2008], lentiviruses seem to escape 
silencing to varying degrees, depending in part on the species and the promoter sequence. 
In certain cases, probably due to the site of genomic integration, retroviral vector expression 
is maintained [Dimos T, et al 2008; Park IH et al. 2008]. Moreover some kind of promoter 
allowed a continued transgene expression that increases the efficiency of iPSC generation 
but on the other side severely impairs iPSCs differentiation both in vivo and in vitro [Sommer 
CA et al 2010]. Spontaneous transgene reactivation may also occur and lead to tumor 
formation [Okita K et al 2007]. Partial reprogramming may have arisen from cells that either 
did not receive all reprogramming factors or expressed the factors with stochiometries or 
expression levels that did not allow for complete reprogramming. 
For the above reasons alternative gene delivery methods were experimented to generate 
transgene-free iPSCs that are suitable for basic research and clinical applications. Recent 
study reported the use of a single lentiviral ‘stem cell cassette’ vector flanked by loxP sites 
(hSTEMCCA-loxP) in order to accomplish efficient reprogramming of normal or diseased 
skin fibroblasts obtained from humans of virtually any age [Somers A et al 2010]. Human 
iPSCs obtained in this way contained a single excisable viral integration, that upon removal 
generates human iPSC free of integrated transgenes. More than 100 lung disease specific 
iPSC lines were generated from individuals with a variety of diseases affecting the 
epithelial, endothelial, or interstitial compartments of the lung, such as Cystic Fibrosis, 
Alpha-1 Antitrypsin Deficiency-related emphysema, Scleroderma, and Sickle Cell Disease. 
An high efficiency of reprogramming was obtained, using minute quantities of viral vector. 
Finally all clones generated with the hSTEMCCA-loxP vector expressed a broad 
complement of ‘stem cell markers’.  
Viruses are currently used to introduce the reprogramming factors into adult cells, but this 
process must be carefully controlled and tested before the technique can lead to useful 
treatments for humans, because sometimes this integration could causes cancers. The 
protocol efficiency by using retro/lentiviruses is low, with a reported reprogramming rates 
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of 0.001% to 1%. [Wernig M et al 2007; Maherali N et al 2007]. The differentiation stage of the 
starting cell appears to impact directly the reprogramming efficiency: mouse hematopoietic 
stem and progenitor cells give rise to iPSCs up to 300 times more efficiently than do their 
terminally-differentiated B- and T-cell counterparts [Emnli S et al 2009]. Also terminally 
differentiated human amniotic fluid (AF) skin cells were  reprogrammed twice as fast and 
yielded nearly a two-hundred percent increase in number, compared to cultured adult skin 
cells, probably because these cells may have an embryonic like epigenetic background, 
which may facilitate and accelerate pluripotency [Galende E et al. 2010]. The ability to 
efficiently and rapidly reprogram terminally differentiated AF skin cells provides an 
abundant iPS cell source for various basic studies and a potential for future patient specific 
personalized therapies [Galende E et al 2010]. 
Significant progress has been made in improving the efficiency and safety of the 
reprogramming technique, such as investigating non-viral delivery strategies [Feng B et al 
2009; Stadtfeld M, et al 2009; Stadtfeld M, et al 2008; Page RL,et al 2009] 
Recent studies have reported on the generation of iPS cells using non viral systems, such as 
plasmids [Kaji K et al 2009], and transposons [Woltjen K et al 2009], all of which allow for 
subsequent transgene removal through the Crelox system or transposases. A feasible way is 
to combine the reprogramming factors into a single polycistronic vector  [Utikal J et al 2009], 
transiently expressing the reprogramming factors required to induce pluripotency. Plasmid 
vectors [Ko K et al 2009] were successfully used to derivate miPSCs, demonstrating that 
proviral insertions are not necessary for iPSC generation. For non-integrating delivery 
systems, the reprogramming rates were very low (approximately 0.0005%). Another 
possible way to induce pluripotency in somatic cells while avoiding the risks of genomic 
modifications is through direct delivery of reprogramming proteins. Such a strategy has 
been reported by different groups [Deng J et al 2009; Doi A et al 2009]. A similar study have 
demonstrated the feasibility of generating iPSCs  by applying recombinant OCT4, SOX2, 
KLF4 and c-MYC proteins which  have been engineered to include a C-terminal poly-
arginine sequence.  This sequence is capable of mediating cell permeation of the 
reprogramming protein factors, which, upon entering the cells, could translocate into their 
nuclei. In combination with valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, 
these protein factors could induce the reprogramming of mouse embryonic fibroblasts 
(MEFs) to form iPSCs. [Zhou H et al 2009]. 
One group even reported that hypoxic treatment can enhance the efficiency of iPSC 
formation [Yoshida Y et al 2009]. These non-genetic strategies have the advantage of being 
more readily reversible, possibly facilitating downstream differentiation processes and 
minimizing any permanent deleterious effects on the cells.  
It is widely accepted that the choice of the delivery method will impact the reprogramming 
efficiency, which is defined as the number of formed colonies divided by the number of cells 
that were effectively transduced with the reprogramming factors [Colman A et al 2009]. 
Besides to the delivery method, the overall efficiency of the protocol is subject to other 
sources of variation that include the transcription factors and target cell type employed, the 
age of the donor, the passage number of the cells (inversely correlated with efficiency), and 
whether the specific protocol includes splitting of cells after infection.  
Researchers have also investigated whether all factors are absolutely necessary. c-Myc gene 
known to promote tumor growth in some cases, was eliminated. Three-factors were 
successfully tested, using the orphan nuclear receptor ESRRB with OCT4 and SOX2. [Feng B 
et al 2009; Wernig M et al 2008]. In subsequent studies the number of genes required for 
www.intechopen.com
Potential Clinical Applications of Embryonic Stem Cells   
 
35 
reprogramming were further reduced [Huangfu D, et al 2008; Hester ME, et al 2009; Kim 
JB,et al 2008; Kim JB,et al. 2009; Kim JB, et al 2009] and researchers identified chemicals that 
can either substitute for or enhance the efficiency of transcription factors in this process 
[Feng B et al 2009]. 
Of the original four transcription factor-encoding genes, OCT4 is the only factor that cannot 
be replaced by other family members and the only one that has been required in every 
reprogramming strategy in either mouse or human cells. Different cell types have been 
reprogrammed, including hepatocytes [Scadcfeld M et al 2008], stomach cells [Aoi T, et al. 
2008], B lymphocytes [Hannal, et al.2008], pancreatic cells [Stadfeld M et al 2008], and neural 
stem cells [Emnli S et al 2008] in the mouse; keratinocytes [Aasen T et al 2008], mesenchymal 
cells [Park H et al 2008], peripheral blood cells [Loh YH et al 2009], and adipose stem cells 
[Sun N et al 2009] in the human; and melanocytes in both species [Utikal J et al 2009] .  
An extensive comparisons between iPSc and ESC to determine pluripotency, gene 
expression, and function of differentiated cell derivatives were made finding some 
differences whose clinical significance in the application to regenerative medicine has to be 
determined yet.  
iPSCs appear to be truly pluripotent, although they are less efficient than ESCs regarding 
the differentiation capacity. 
Moreover both iPSCs and ESCs appear to have similar defence mechanisms to counteract 
the production of DNA-damaging reactive oxygen species, thereby conferring the cells with 
comparable capabilities to maintain genomic integrity [Armstrong L et al 2010]. 
Comparative genomic analyses between hiPSCs and ESCs revealed differences in the 
expression of some genes due to detectable differences in epigenetic methylation status  
[Chin MH, et al 2009; Deng J, et al 2009; Doi A,et al  2009]. 
Recently gene-expression profiles performed comparing iPSCs and ESCs from the same 
species revealed that these cells differ no more than observed variability among individual 
ESC lines [ Mikkelsen TS et al. 2008]. A more recent studies reported a detailed comparison 
of global chromatin structure and gene expression data for a panel of human ESCs and 
iPSCs, demonstrating that the transcriptional programs of ESCs and iPSCs show very few 
consistent differences [Guenther MG et al 2010]. 
An iPSC may carry a genetic “memory” of the cell type that it once was, and this “memory” 
will likely influence its ability to be reprogrammed. Understanding how this memory varies 
among different cell types and tissues will be necessary to reprogram them successfully. 
Although much additional research is needed, investigators are beginning to focus on the 
potential utility of iPSCs which represent patient-specific stem cell lines, useful for drug 
development, modeling of disease, and transplantation medicine. It is now possible to 
derive immune-matched supply of pluripotent cells from patient’s tissue, avoiding rejection 
by the immune system. Patients who receive ESC-derived cells or tissues may face the same 
complications that result from organ transplantation (for example, immunorejection, graft-
versus-host disease, and need for immunosuppression). In case of iPSCs, the need for 
immunosuppressive drugs to accompany the cell transplant would be lessened and perhaps 
eliminated altogether. Reprogrammed cells could be directed to produce the cell types that 
are compromised or destroyed by the disease in question. Moreover induced pluripotent 
cells offer the obvious advantage that they are not derived from embryonic tissues, thereby 
circumventing the ethical issues that surround use of these materials.  
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iPSCs have the potential to become multipurpose research and clinical tools to understand 
and model diseases, develop and screen candidate drugs, and deliver cell-replacement 
therapy to support regenerative medicine.  
10.1 Potential medical application of iPSCs 
Easily-accessible cell types (such as skin fibroblasts) could be biopsied from a patient and 
reprogrammed, effectively recapitulating the patient’s disease in a culture dish. The 
usefulness of iPS cells to model a disease in a culture dish is based on the unique capacity of 
these cells to continuously self-renew and their potential to give rise to all cell types in the 
human body [Murry CE and Keller G  2008; Friedrich Ben-Nun I, Benveniscy N  2006]. The 
potential use of iPSCs as treatments for various disorders has been proposed and tested on 
in vitro and/or in vivo animal models, with promising results. Direct injection of (non-
autologous) iPSCs into the myocardium of immunocompetent mouse models of acute 
myocardial infarction led to stable engraftment and substantial improvement in  cardiac 
function [Nelson TJ, et al 2009]. On the other hand, dopamine neurons differentiated from 
iPSCs have been grafted  into the striatum of Parkinsonian rats, showing a motor function 
recovery [Wernig M et al 2008]. A mouse model of haemophilia A has also been successfully 
treated by iPSC-derived endothelial cells, which express wild-type Factor VIII, directly 
injected into the liver [Xu D et al 2009]. Furthermore, neural progenitors differentiated from 
iPSCs have shown further differentiation into neural and glial cells after transplantation into 
the cochlea, which suggests potential application in the treatment of hearing loss due to 
spiral ganglion neuron degeneration [Nishimura K et al 2009].  
Thus, iPSCs such as ESCs could provide a limitless reservoir of cell types that in many cases 
were nor previously possible to obtain. Ideally, iPSC-based therapies in the future will rely 
on the isolation of skin fibroblasts or keratinocytes, their reprogramming into iPSCs, and the 
correction of the genetic defect followed by differentiation into the desired cell type and 
transplantation. 
Several disease-specific iPSCs are being generated such as Adenosine Deaminase deficiency-
related Severe Combined Immunodeficiency, Shwachman¬Bodian-Diamond syndrome, 
Gaucher disease type III, Duchenne and Becker Muscular Dystrophies, Parkinson’s disease, 
Huntington’s disease, type 1 Diabetes Mellitus, Down Syndrome/trisomy 21, and Spinal 
Muscular Atrophy [Ebert AD et al 2009; Park I-H et al 2008] in order to use them to model 
disease pathology. For example, iPSCs created from skin fibroblasts taken from a child with 
Spinal Muscular Atrophy were used to generate motor neurons that showed selective 
deficits compared to those derived from the child’s unaffected mother [Ebert AD et al 2009]. 
Another study reported the potential of iPS cell technology to model disease pathogenesis 
and  treatment by creating iPS cell lines from patients with familial dysauronomia (FD), a 
neuropathy caused by a point mutation in theB kinase complex-associated protein 
(IKBKAP) gene [Lee G et al 2009]. This mutation leads to a tissue-specific splicing defect that 
was recapitulated in iPS cell-derived tissues, by showing in vitro specific defects in 
neurogenesis and migration of neural crest precursors, tissues that were previously 
unobtainable.  
Before any iPSC derivatives can be considered for applied cell therapy, the potential for 
tumor formation must also be addressed fully. Furthermore, in proposed autologous 
therapy applications, somatic DNA mutations (e.g., non-inherited mutations that have 
accumulated during the person’s lifetime) retained in the iPSCs and their derivatives could 
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potentially impact downstream cellular function or promote tumour formation (an issue 
that may possibly be circumvented by creating iPSCs from a “youthful” cell source such as 
umbilical cord blood) [Haase A et al. 2009]. 
On the basis of the unlimited capacity to be propagated in vitro, iPSCs are good targets for 
genetic manipulation by gene therapy or gene correction by homologous recombination. 
Classical gene augmentation therapy has also been applied to iPSCs derived from Duchenne 
Muscular Dystrophy (DMD) [Kazuki Y et al 2009] and Fanconi Anaemia [Raya A et al 
2009]patients. In the former case, a human artificial chromosome (HAC), carrying the full 
length, wild-type dystrophin genomic sequence [Kazuki Y et al 2009] was introduced into 
iPS cells generated using retroviral vectors. For Fanconi Anemia disease, gene therapy 
approach using lentiviral vectors, carrying FANCA or FANCD2 genes, were performed 
before iPS generation [Raya A et al 2009]. The authors demonstrated that gene augmentation 
was a pre-requisite for successful iPSC generation, as the genetic instability of the mutant 
fibroblasts made them non permissive for iPS cell generation. [Raya A et al 2009]. The 
resultant iPSCs were shown to be phenotypically disease-free, with a functional FA 
pathway, as well as haematopoietic progenitors derived from these iPSCs [Raya A et al 
2009]. 
Gene targeting by spontaneous homologous recombination has similarly been demonstrated 
in iPSCs [Hanna et al 2007], by successfully treating the sickle cell anemia mouse model  
mouse with autologous iPSCs, whose β-globin gene has been corrected by homologous 
recombination [Hanna et al 2007]. Reprogrammed fibroblasts from an anemic mouse were 
corrected by homologous recombination, successfully differentiated into hematopoietic 
progenitors, and subsequently transplanted back into the mouse whose bone marrow has 
been destroyed by irradiation.  
As result of the treatment, a substantial clinical improvement was observed in the various 
disease phenotypes, providing a paradigm for future preclinical and clinical studies 
regarding gene targeting in iPSCs. As demonstrated the potential of iPS cell technology is 
enormous for treating genetic diseases. However it is also mandatory to develop better 
methods of gene therapy, as genetic integration of lentiviral vectors used for expressing 
therapeutic transgene maybe oncogenic [Hacein-Bey-Abina S, et al 2008]. Regarding their 
use in gene therapy protocol, the efficiency of homologous recombination in ES and iPS cells 
remains extremely low [Zwaka TP et al 2003], in this direction recent advancements were 
reported with zinc finger nucleases [Zou et al 2009; Hockemeyer D et al 2009].  
11. Predictive toxicology and drug discovery 
The unique properties of pluripotent-stem cells-based models give them the potential to 
revolutionize the earliest steps of drug discovery and, in particular, the stages of 
pathological and toxicology modelling, by providing physiological models for any human 
cell type at the desired amount. In particular, hepatotoxicity and cardiotoxicity are the 
principal causes of drug failure during preclinical testing, while the variability in individual 
responses to potential therapeutic agents is also a major problem in effective drug 
development [Rubin LL 2004; Davila ]C et al 2004]. Currently new drug development 
continues to suffer for the limited ability to predict the efficacy and toxicity of drugs 
developed and tested in animal models. As a result, several promising treatments in rodents 
and non human primates fail in human clinical trials. Differentiated cells and/or tissues 
derived from human iPS cells can address this issue by providing an unlimited source of 
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cells to screen drug efficacy and toxicity. The human cellular models used in this field are 
mainly of two types: primary cells coming from patients’ samples, and transformed cell 
lines derived from tumours or resulting from genetic manipulations. Although these 
resources have widely demonstrated their utility, they present well-known limitations in 
terms of supply and relevance respectively. This is because primary human cells are difficult 
to standardize and to obtain in sufficient number for toxicity testing while human cell lines 
are often derived from carcinogenic origin and could have different properties than non-
malignant cells.  
Moreover specific ethnic and idiosyncratic differences in drug action and metabolism can 
also be evaluated with iPS cells derived from selected individuals thereby making possible 
customized treatments for individual conditions. Besides the possibility to give rise to high 
predictive phenotypic models, pluripotent stem cells offer the possibility to explore human 
polymorphisms associated with drug disposition. Several gene products, including drug-
metabolizing enzymes and transporters or transcription factors, are known to be involved in 
drug disposition, and some of them display well-established associations between genotype 
and metabolism [Katz, DA, et al 2008]. The advantage of iPS cell technology is that it allows 
for the first time the generation of a library of cell lines that may represent the genetic and 
potentially epigenetic variations of a broad spectrum of the population.  
Besides the common characteristics and properties that they share with hESCs, iPSCs 
present the additional advantage that they could be derived from any patient whose disease 
is to be studied. Therefore iPSCs allow the access both to diseases whose mutation is known 
and  pathologies whose causal mutation is unknown. Pluripotent SCs can be an useful tool 
to study disease mechanisms, either at the undifferentiated stage or in specific cell types. 
Moreover, they enable the expression of the pathology in the specific cellular model to be 
correlated with the patient’s symptoms. 
They can theoretically provide relevant models for any pathology, including neurological 
disorders and rare diseases that are difficult to analyse in vitro. Moreover, as they are 
compatible with a miniaturized format, they open the way to screening techniques using 
genomic resources and chemical libraries.  
The use of this tool in high-throughput screening assays could allow better prediction of the 
toxicology  and the therapeutic responses induced by newly developed drugs offering 
insight into the underlying mechanisms. The net result of this approach would substantially 
decrease the risk and cost associated with early-stage c1inical trials and could lead toward a 
more personalized approach in drug administration. 
Since the first description of iPS cell generation three years ago, there has been remarkable 
progress toward clinical implementation of reprogramming technologies. Before iPSCs can 
be used for clinical purposes, few issues need to be addressed. The recent successes in iPS 
cell derivation without viral vectors and genomic integration from human cells has brought 
the realization of the therapeutic potential of iPS cell technology closer than ever. 
Importantly, however, the suitability of individual iPS cell derivation methods for 
generating cell populations for cell replacement therapy, disease modeling, and drug 
discovery remains to be widely demonstrated, and studies assessing the equivalence of 
different types of iPS cells are ongoing.  
Moreover the long term efficacy of iPSCs treatments has to be tested considering as 
fundamental both the survival and the functional integration of the iPSCs, after introduced 
them into the patient.  
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